Skip to main content

Free Content Rates and risk factors for discontinuation of rifampicin

Download Article:
(PDF 181.4912109375 kb)
SETTING: All patients with culture-confirmed, rifampin-susceptible Mycobacterium tuberculosis diagnosed during a 20-month period in New York City, who were started on a rifampin-containing regimen and received ≥60 days of treatment.

OBJECTIVE: To identify rates of and reasons for rifampin discontinuation.

DESIGN: Retrospective case-control study using surveillance data and medical record reviews. Discontinuation due to thrombocytopenia, creatinine >2.0 mg/dl, bilirubin >2.0 mg/dl or severe reactions (generalized rash, persistent drug fever, or severe interference with methadone metabolism) were defined as appropriate for discontinuation of rifampin. All other reactions were classified as inappropriate.

RESULTS: Of 3520 patients, rifampin was discontinued in 68 (1.9%); of these, 57% had rifampin discontinued unnecessarily. Treatment by an inexperienced provider (adjusted odds ratio [ORadj] 4.0; 95% confidence interval [CI] 1.9–8.5), race (ORadj 3.1; 95%CI 1.4–6.9), history of previous treatment (ORadj 4.8; 95%CI 1.9–12.5), and history of methadone drug treatment (ORadj 12.6; 95%CI 5.3–29.9) were all associated with inappropriate rifampin discontinuation.

CONCLUSION: True intolerance was rare, even among those patients infected with the human immunodeficiency virus. Most patients with minor reactions can successfully complete treatment with rifampin, particularly if managed by a physician experienced in the treatment of tuberculosis.
No References
No Citations
No Supplementary Data
No Data/Media
No Metrics

Keywords: adverse reaction; rifampicin discontinuation; tuberculosis

Document Type: Regular Paper

Affiliations: New York City Department of Health, Bureau of Tuberculosis Control, New York, New York, USA

Publication date: 2000-02-01

More about this publication?
  • The International Journal of Tuberculosis and Lung Disease publishes articles on all aspects of lung health, including public health-related issues such as training programmes, cost-benefit analysis, legislation, epidemiology, intervention studies and health systems research. The IJTLD is dedicated to the continuing education of physicians and health personnel and the dissemination of information on tuberculosis and lung health world-wide.

    Certain IJTLD articles are selected for translation into French, Spanish, Chinese or Russian. They are available on the Union website

  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • International Journal of Tuberculosis and Lung Disease
  • Public Health Action
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more